Skip directly to content

TAG, PrEP4All Joint Comment on DESCOVY for FDA Hearing, 8-7-19

August 7, 2019 – TAG and PrEP4All submitted the following joint comment to the FDA Antimicrobial Drugs Advisory Committee on August 7, 2019 about the supplemental new drug application for DESCOVY (tenofovir alafenamide fumarate \ emtricitabine, or TAF\FTC) for an indication for HIV pre-exposure prophylaxis (PrEP).  TAG and PrEP4All express concerns about the limited data available to support a PrEP indication for TAF\FTC – especially in key populations such as cisgender women and people of color – and about Gilead's conduct in delaying research and inflated claims about the benefits of TAF\FTC.

Read/Download the Full Comment